Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Roberto Mignone is Director at Guardant Health. OQRO lists 3 transactions filed with the SEC under this name, the latest on Oct 22, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
Roberto Mignone bought shares on the open market in 2015 and 2018, and has not bought since 2018 across 2 companies. Sales in 1 of the 12 years since 2015.
Roberto Mignone reported 5 open-market purchases and 2 sales since 2015; purchases in 2 different years, most recently 2018.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $15.1M2×2 trades |
| 2018 | $14.4M2×2 trades | — |
| 2015 | $1.41M3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Guardant HealthGH
2 disclosures · Oct 2026
Oct 21, 2026264disclosed Oct 22
DetailsOfficial recordOct 21, 2026264disclosed Oct 22
DetailsOfficial recordTeva Pharmaceutical IndustriesTEVA
Dec 20, 2024Sold~$6.29Mdisclosed Dec 26
DetailsOfficial recordAs of the latest filing on , Roberto Mignone reported holding 695,000 shares of Teva Pharmaceutical Industries (TEVA), worth about $27.3M at the last close of $39 (Nov 20, 2026), held through a [see footnote]. Holdings are also on file at Guardant Health (GH); together they are worth about $28.8M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Teva Pharmaceutical Industries TEVA | 695,000 | 695K [see footnote] | $39 | $27.3M | Dec 20, 2024 |
| Guardant Health GH | 10,538 | 11K direct | $146 | $1.54M | Oct 21, 2026 |
Is this Roberto Mignone’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Roberto Mignone reported 2 open-market purchases and 2 sales here, 2018 to 2024.
Roberto Mignone reported 3 open-market purchases and 0 sales here, 2015.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Dec 20, 2024, Roberto Mignone reported holding 695,000 shares of Teva Pharmaceutical Industries (TEVA), held indirectly. At the last close of $39 on Nov 20, 2026, that is about $27.3M. This is the stake disclosed in filings, not a net worth.
No public filing gives Roberto Mignone's net worth. What SEC Form 4 shows is the stock stake: 695,000 shares of Teva Pharmaceutical Industries (TEVA), about $27.3M at the last close, plus holdings in 1 other company, about $28.8M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Roberto Mignone bought shares on the open market in 2015 and 2018, and has not bought since 2018 across 2 companies. Sales in 1 of the 12 years since 2015.
In SEC filings since 2015: the latest open-market purchase is from 2018; the latest open-market sale is from 2024.
2 companies: Teva Pharmaceutical Industries (TEVA, 2018–2024), Cardiff Oncology (CRDF, 2015).